Lumenis Aesthetic Devices: FDA Clearances and MAUDE Safety Footprint

Lumenis has 65 FDA 510(k) clearances (mostly laser code GEX) from 1982 to 2025; 1,192 MAUDE reports name its aesthetic devices (LightSheer, M22, UltraPulse, AcuPulse), while the larger 4,743-report manufacturer total is dominated by its surgical/urology holmium lasers.

Lumenis holds 65 FDA 510(k) clearances under the applicant name "Lumenis" (64 under the general Powered Laser Surgical Instrument product code GEX and 1 under ONG), spanning from March 8, 1982 (the Coherent-era Model 450XL CO2 laser) through April 16, 2025. The company was formed from the merger of Israel's ESC Medical Systems and Coherent Medical Group, and is privately held (headquartered in Yokneam, Israel) following major private equity transactions with XIO Group in 2015 and Baring Private Equity Asia in 2019. Its current aesthetic line includes the LightSheer family (diode hair removal), M22/Stellar M22 (IPL multi-platform), UltraPulse/AcuPulse (CO2 resurfacing), Splendor X, Legend Pro (RF), and NuEra Tight. In the openFDA MAUDE safety database, brand-name matching for Lumenis's aesthetic devices (LightSheer, M22, UltraPulse, AcuPulse, Splendor X, and Quantum) yields 1,192 reports; the broader manufacturer match of 4,743 is heavily dominated by its surgical/urology holmium laser lines (such as Moses, SlimLine, and the VersaPulse PowerSuite), where all 7 reported deaths and the majority of device malfunctions reside, rather than in the aesthetic dermatology devices. (A still-broader brand-name match that also sweeps in the dual-use VersaPulse system reaches about 1,676 reports, but the PowerSuite variant is a surgical/urology holmium platform and is excluded from the aesthetic count here.)

---

How many FDA 510(k) clearances does Lumenis hold, and what is the lineage from Coherent to today?

Regulatory clearance analysis

A search of the FDA’s Premarket Notification 510(k) database for the applicant "Lumenis" yields 65 total clearances.

• Product Code GEX (Powered Laser Surgical Instrument): 64 clearances. This is the primary regulatory pathway for medical lasers, intense pulsed light systems, and energy-based aesthetic devices.
• Product Code ONG (Laser, Surgical, Gynecological/Urological): 1 clearance.

The dates of these clearances span more than four decades, reflecting the development of medical laser technology:

• Earliest Clearance: March 8, 1982, for the Coherent Model 450XL CO2 Surgical Laser (K820327). This reflects the company's heritage under the Coherent Medical Group before it was folded into Lumenis.
• Latest Clearance: April 16, 2025.
• Key Mid-Era Milestones: Cleared systems include the Lumenis UltraPulse Encore Carbon Dioxide Surgical Laser (K022060) on October 30, 2002, and the LightSheer Duet Laser System (K053628) on April 7, 2006.

Corporate heritage: ESC Medical Systems and Coherent Medical Group

The name "Lumenis" was adopted in 2001, but the company's origins lie in two separate entities:

1. ESC Medical Systems: Founded in Israel in 1991, ESC pioneered intense pulsed light (IPL) technology, which uses a broad spectrum of light (filtered to target specific chromophores) instead of a single, coherent laser beam. Under the leadership of Shimon Eckhouse, ESC grew rapidly by acquiring competitors, including Laser Industries (Sharplan) in 1998.
2. Coherent Medical Group: Coherent, Inc. was a major laser manufacturer in California. In 2001, ESC Medical Systems acquired Coherent's medical division for approximately $200 million. The combined entity was renamed Lumenis, representing the Latin word for "light" (lumen).

This merger combined ESC’s expertise in IPL and aesthetic technologies with Coherent’s surgical, ophthalmic, and high-power laser portfolios, creating a medical laser manufacturer with global reach.

---

What is Lumenis's current aesthetic device lineup by technology?

Lumenis categorizes its aesthetic devices into four technological pillars: diode lasers, intense pulsed light (IPL), carbon dioxide (CO2) resurfacing lasers, and radiofrequency (RF) systems.

Diode lasers: LightSheer and Splendor X

The LightSheer family uses semiconductor diode arrays. The systems are designed for hair removal and are configured with either ChillTip contact sapphire cooling or High-Speed vacuum-assist handpieces. The vacuum-assist handpieces temporarily stretch the skin to dilute melanin density and compress capillary blood vessels, allowing for safe treatment at lower energy levels.

The Splendor X utilizes a technology licensed/manufactured in partnership with Bios S.R.L. It is cleared under 510(k) K241407 and features a synchronized dual-wavelength emission called Blend X. This technology simultaneously fires 755 nm (Alexandrite) and 1064 nm (Nd:YAG) in adjustable ratios. This allows the operator to customize the treatment based on the patient's skin type, targeting deep follicles with the Nd:YAG while utilizing the high melanin absorption of the Alexandrite.

Intense Pulsed Light (IPL): M22 and Stellar M22

The M22 and Stellar M22 are modular multi-application platforms. The core of the platform is the Universal IPL handpiece, which utilizes Optimal Pulse Technology (OPT). OPT allows the operator to split a single pulse into multiple sub-pulses with flat-top energy delivery, preventing thermal energy spikes that could burn the skin.

• Cut-off Filters: The M22 uses interchangeable cut-off filters (515 nm, 560 nm, 590 nm, 615 nm, 640 nm, 695 nm, 755 nm) to target different depths and chromophores.
• Specialized Filters: The Stellar M22 added specialized filters: the Vascular Filter (which combines two bands, 530–650 nm and 900–1200 nm, to target superficial and deep vessels) and the Acne Filter (which uses 400–600 nm for target porphyrins and 800–1200 nm to target sebaceous glands).

Carbon Dioxide (CO2) lasers: UltraPulse and AcuPulse

CO2 lasers operate at a wavelength of 10,600 nm, which is strongly absorbed by water in skin tissue. This leads to rapid ablation of the epidermis and superficial dermis, triggering neocollagenesis. For patient-facing expectations, see our CO2 laser cost and downtime guide and CO2 laser recovery timeline.

• UltraPulse: Known for its high energy delivery. It uses short pulse widths (under 1 ms) to ablate tissue before heat can diffuse into surrounding areas. This reduces the risk of thermal damage and scarring compared to slower CO2 systems. Its SCAAR FX mode delivers up to 150 mJ per pulse, penetrating up to 4 mm into the skin to remodel deep surgical, burn, and acne scars.
• AcuPulse: Designed as a more compact and versatile CO2 system. It features an integrated scanner and offers both superficial fractional ablation (AcuScan) and deeper fractional treatment, making it suitable for standard aesthetic resurfacing.

Recent Additions and Emerging Clearances: FoLix and OptiLight

Lumenis has continued to expand its regulatory and clinical footprint beyond traditional dermatology verticals, securing clearances for specialized optical medical treatments:

• FoLix™ Hair Loss Treatment (2024): In 2024, Lumenis secured FDA clearance for FoLix, a fractional laser platform specifically designed to address hair thinning. It operates by delivering fractional laser micro-pulses to the scalp. This creates controlled micro-zones of thermal injury, stimulating localized growth factor expression, increasing follicular blood supply, and revitalizing dormant hair follicles. It represents the first fractional laser specifically cleared for hair loss, expanding the company's devices profile into trichology.
• OptiLight™ Dry Eye Treatment (2021 De Novo): In 2021, the FDA granted De Novo clearance for Lumenis's OptiLight. This device is a specialized intense pulsed light (IPL) system designed to treat dry eye disease caused by meibomian gland dysfunction (MGD). By delivering flat-top pulses of light across the periorbital region, OptiLight helps reduce inflammatory cytokines, close abnormal telangiectatic vessels that contribute to chronic gland inflammation, and liquefy hardened meibum within the glands. This clearance established IPL as an accepted medical therapy for dry eye.

---

Detailed Clinical Protocols and Parameters

To ensure safety and maximize efficacy, Lumenis publishes specific treatment guidelines for its primary aesthetic systems. Below are representative clinical parameters for the M22 IPL and Legend Pro RF systems based on patient indications.

Stellar M22 IPL Photorejuvenation Protocol

The Stellar M22 IPL system utilizes interchangeable cut-off filters and sequential pulsing.

• Fitzpatrick Skin Type I–II (Fair Skin):
  • Indication: Telangiectasia and solar lentigines.
  • Filter: 515 nm or 560 nm.
  • Fluence: 15–20 J/cm².
  • Pulse Delay: 20–30 ms.
  • Cooling: 4°C.
  • Endpoint: Mild transient erythema and immediate darkening of pigmented lesions.
• Fitzpatrick Skin Type III–IV (Olive/Light Brown Skin):
  • Indication: Diffuse redness and pigmentation.
  • Filter: 590 nm or 615 nm.
  • Fluence: 12–16 J/cm².
  • Pulse Delay: 35–45 ms.
  • Cooling: 5°C.
  • Endpoint: Mild erythema; avoid any epidermal graying.
• Fitzpatrick Skin Type V (Dark Brown Skin):
  • Indication: Mild vascular redness (IPL used with extreme caution).
  • Filter: 640 nm or 695 nm.
  • Fluence: 10–12 J/cm².
  • Pulse Delay: 50–60 ms.
  • Cooling: 5°C.
  • Endpoint: Sub-erythemal warming only.

Legend Pro RF Microneedling (VoluDerm) Protocol

VoluDerm uses RF-assisted ultra-thin electrodes to create micro-ablation channels.

• Treatment Area: Full Face (Wrinkles and Skin Laxity):
  • Electrode Tip: Gen100 (100 micro-needles, 0.5 mm depth) or Gen36 (36 needles for thicker scars).
  • RF Power: 10–15 W.
  • Pulse Duration: 200–300 ms.
  • Passes: 1–2 passes over target zones.
  • Clinical Endpoint: Post-treatment erythema, mild edema, and micro-crusting resolving in 3–5 days.

---

What does the MAUDE safety profile show, and why does the manufacturer total dwarf the aesthetic-device total?

The urology vs. aesthetics split

When assessing the post-market safety record of Lumenis in the FDA’s MAUDE database, a naive search for the manufacturer "Lumenis" returns 4,743 total adverse event reports. This high number is sometimes cited by critics or competitors as a safety concern.

However, a detailed analysis of the reports reveals that the manufacturer-level total is heavily dominated by Lumenis's former Surgical and Urology division, which was sold to Boston Scientific in 2021.

• The Urology Portfolio: Urology devices utilize high-power holmium:YAG lasers (such as the Moses 200 D/F/L, Moses Pulse, SlimLine fibers, and VersaPulse PowerSuite) to fragment kidney stones (lithotripsy) and perform prostate resections (HoLEP).
• The Malfunction Concentration: Of the 4,743 reports, 3,376 are classified as Malfunctions (71.17%), with urology holmium fibers breaking, splitting, or failing to transmit power during endoscopic procedures. These surgical fibers are fragile and subject to high stress within the urinary tract.
• Serious Adverse Events: The 4,743 manufacturer reports include 7 Deaths. Every one of these deaths was associated with a urological or surgical procedure (e.g., retroperitoneal hemorrhage during lithotripsy, septic shock, or vascular damage during surgical resections). None of the reported deaths were associated with Lumenis aesthetic or dermatological treatments.

Aesthetic device MAUDE reports analysis

To isolate the safety footprint of the aesthetic division, we ran a brand-name search across the MAUDE database for Lumenis's core aesthetic platforms (including LightSheer, M22, UltraPulse, AcuPulse, ResurFX, Stellar, Splendor X, and Quantum). The dual-use VersaPulse line is excluded here because, in the MAUDE data, its reports are dominated by the surgical/urology VersaPulse PowerSuite holmium system (degrading fibers during lithotripsy and HoLEP) rather than aesthetic use — it is covered in the urology split above.

This aesthetic brand-level query yielded 1,192 total reports. The event types and distribution across these aesthetic devices are detailed below:

• Event Classification:
  • Injuries: 756 reports (~63%). (Primarily epidermal burns, blistering, post-treatment hyperpigmentation, scarring, and ocular irritation).
  • Malfunctions: 300 reports (~25%). (Software errors, laser calibration failures, cooling system leakage, and handpiece connection issues).
  • Other / Unclassified: 136 reports (~12%).

The distribution of reports across the main aesthetic platforms is as follows (the ten most-reported platforms account for 761 of the 1,192 reports; the remainder sit across Quantum, LightSheer XC, and smaller variants):

Interpretation of aesthetic injuries

The injury reports for the aesthetic devices are generally associated with operator settings or patient selection rather than mechanical device failure:

1. M22 IPL Burns: Reports of burns and blisters with the M22 are almost exclusively linked to:
   • Incorrect Filter Selection: Using a short wavelength filter (e.g., 515 nm or 560 nm) on Fitzpatrick IV or V skin, which causes excessive epidermal melanin absorption.
   • Inadequate Gel: Firing the IPL without a consistent layer of clear coupling gel, which leads to optical mismatch and localized burns.
2. LightSheer Vacuum Bruising: The vacuum handpiece on the LightSheer Duet and Desire can cause petechiae (small purple spots from broken capillaries) or bruising if the suction is applied to fragile skin, or if the handpiece is held in place for too long.
3. CO2 Laser Resurfacing Scarring: Reports for the UltraPulse and AcuPulse systems describe prolonged redness (erythema), swelling, and occasional scarring. These are known risks of ablative fractional CO2 resurfacing, particularly when treating thin neck skin or when patients fail to follow post-procedure wound care guidelines.

---

Corporate heritage and the Bausch Health/Solta distinction

Lumenis’s ownership history has undergone several transitions over the past two decades.

Corporate Transaction Timeline

1. 2001 (Acquisition & Rebrand): On April 30, 2001, ESC Medical Systems acquires Coherent Inc.'s Medical Group for ~$203 million; the combined company is renamed Lumenis in September 2001.
2. 2006 (Acquisition): A consortium of LM Partners L.P. and Ofer Hi-Tech Group acquires a 75% stake in Lumenis.
3. 2015 (Acquisition): XIO Group acquires Lumenis for approximately $510 million.
4. 2019 (Acquisition): Baring Private Equity Asia (BPEA) acquires Lumenis in a transaction valued at over $1.0 billion.
5. 2021 (Divestiture): BPEA sells the Lumenis surgical/urology laser division to Boston Scientific for $1.07 billion. BPEA (now part of EQT Private Capital Asia) retains the aesthetics and ophthalmology divisions.

Correcting the Bausch Health / Solta Medical conflation

A common misconception in the aesthetic industry is that Lumenis is owned by Bausch Health (formerly Valeant Pharmaceuticals) or is part of Solta Medical.

• Solta Medical is the aesthetic device division of Bausch Health. Its product portfolio includes Thermage FLX (radiofrequency skin tightening), Fraxel (fractional erbium resurfacing), Clear + Brilliant (gentle fractional resurfacing), and Liposonix (ultrasound fat reduction).
• Lumenis is a completely separate entity. It does not share technology, manufacturing facilities, or corporate parentage with Solta Medical or Bausch Health. Solta Medical operates under Bausch Health; in a December 1, 2025 transaction, Solta Medical acquired the Shibo Group (Wuhan Shibo Zhenmei Technology, its long-time China distribution partner) to localize Chinese operations — Solta was the acquirer, not the target. Lumenis, meanwhile, remains a private company under the ownership of EQT Private Capital Asia.

---

Frequently Asked Questions

Who owns Lumenis today, and how does it relate to Solta/Bausch (Thermage, Fraxel)?

Lumenis is privately held by EQT Private Capital Asia (formerly Baring Private Equity Asia), which acquired the company in 2019. In 2021, the surgical and urology laser division was sold to Boston Scientific for $1.07 billion, while EQT retained the aesthetics and ophthalmology divisions.

Lumenis is entirely independent of Solta Medical and Bausch Health. Solta Medical is the aesthetic arm of Bausch Health and owns competing platforms such as Thermage FLX, Fraxel, and Clear + Brilliant.

Are the MAUDE injury and death reports a safety concern for Lumenis aesthetic devices specifically?

No. While a search for "Lumenis" in the FDA’s MAUDE database returns 4,743 adverse event reports and 7 deaths, a detailed analysis shows that:

1. Deaths: All 7 deaths were associated with urological surgery (e.g., lithotripsy or prostate resections) using holmium lasers. There are zero reported deaths associated with Lumenis aesthetic or cosmetic devices.
2. Malfunctions: The majority of malfunctions involve fragile urological laser fibers rather than aesthetic consoles or handpieces.
3. Aesthetic Injuries: The 1,192 reports associated with aesthetic systems (like M22 IPL or LightSheer diode lasers) are primarily transient epidermal burns and pigmentary changes. These are typical risks of energy-based aesthetic devices and are usually caused by operator setting errors rather than device failure.

---

Questions to Ask a Lumenis Device Distributor or Provider

For med spa owners, medical directors, and clinicians looking to acquire pre-owned or new Lumenis devices, or for patients seeking treatment, the following questions should be asked to ensure regulatory compliance and safety:

1. "Is the device covered under an active manufacturer service contract, and have the laser cavities been calibrated within the past 12 months?"
   • Why: CO2 laser tubes (UltraPulse/AcuPulse) and flashlamps (M22) degrade over time, leading to unstable energy output. Calibration verifies that the delivered fluence matches the display settings.
2. "Is this a 'Stellar' M22 or a legacy M22 console, and what cut-off filters are included?"
   • Why: Legacy M22 consoles may lack newer firmware updates and optimized pulse technology (OPT) safety features. Ensure the filter set includes the vascular and acne filters if you plan to treat those indications.
3. "For pre-owned CO2 lasers, what is the current shot count on the laser tube, and is it a sealed metal tube or glass tube?"
   • Why: Refurbishing a depleted CO2 laser tube can cost between $10,000 and $20,000. Knowing the tube's usage helps estimate the remaining operational lifespan before service is required.
4. "For patients: What cooling parameters will you use on the LightSheer handpiece during my treatment?"
   • Why: The operator should confirm they are using contact cooling (ChillTip at 4°C) or adjusting the vacuum-assist level to protect the skin during hair removal.

---

Sources

• U.S. Food and Drug Administration. "510(k) Premarket Notification Database: Coherent Model 450XL CO2 Laser (K820327)." FDA, 1982. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K820327
• U.S. Food and Drug Administration. "510(k) Premarket Notification Database: LightSheer Duet (K053628)." FDA, 2006. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K053628
• U.S. Food and Drug Administration. "510(k) Premarket Notification Database: Stellar M22 (K193500)." FDA, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K193500
• U.S. Food and Drug Administration. "510(k) Premarket Notification Database: UltraPulse Encore (K022060)." FDA, 2002. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K022060
• Boston Scientific. "Boston Scientific Completes Acquisition of Lumenis Surgical Business." Boston Scientific Press Release, 2021. https://news.bostonscientific.com/2021-09-01-Boston-Scientific-Completes-Acquisition-of-the-Lumenis-Surgical-Business
• Bausch Health Companies Inc. "Bausch Health / Solta Medical Transactional Updates." Bausch Investor Relations, 2025. https://ir.bauschhealth.com/news-releases/2025/12-01-2025
• Globes. "Baring Private Equity Asia to acquire Lumenis for over $1 billion." Globes Israel Business News, 2019. https://en.globes.co.il/en/article-behind-the-lumenis-makeover-1001363552
• Photonics Media. "ESC Acquires Coherent's Medical Group." Photonics Spectra, 2001. https://www.photonics.com/Articles/ESC-Acquires-Coherentrsquos-Medical-Group/a8733
• U.S. Food and Drug Administration. "Manufacturer and User Facility Device Experience (MAUDE) Database." FDA, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM